GPRC5D Protein-VLP, Human, Recombinant

GPRC5D Protein-VLP, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 38.80 kDa and the accession number is Q9NZD1-1.

GPRC5D Protein-VLP, Human, Recombinant

パッケージサイズ	在庫状況	単価(税別)
20 μg	約5 days	￥ 192,500
100 μg	約5 days	￥ 383,500
500 μg	約5 days	￥ 1,219,000

バルクのお問い合わせ

説明	GPRC5D Protein-VLP, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 38.80 kDa and the accession number is Q9NZD1-1.

Species	Human
Expression Host	HEK293 Cells
Tag	Tag Free
Accession Number	Q9NZD1-1
別名	GPRC5D
Construction	Human GPRC5D (Q9NZD1-1) (Met1-Val345)
分子量	38.80 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Supplied as sterile solution in 50 mM HEPES, 150 mM NaCI, 10% Trehalose, pH 7.2.
Stability & Storage	It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
Research Background	Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells.

参考文献

1. Eric L. Smith, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 2019. 2. Christie, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 2021. 3. Tatsushi Kodama, et al. Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma. Mol Cancer Ther 1 September 2019.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

GPRC5D Protein-VLP, Human, Recombinant

参考文献

Calculator

技術サポート

Keywords